Included in the formulation
АТХ:A.02.B.C Proton pump inhibitors
A.02.B.C.02 Pantoprazole
Pharmacodynamics:Specific proton pump inhibitor. In parietal cells, the stomach is metabolized to active sulfonamide derivatives that inactivate the sulfhydryl groups of H+TO+ATPase. Reduces basal and stimulated secretion of hydrochloric acid, blocking the final stage of its synthesis. At a dose of 30 mg inhibits the production of hydrochloric acid to 97%.Has no effect on the motor function of the gastrointestinal tract. Pharmacological effect increases in the first 4 days of use. After the end of the intake for 39 hours, the acidity is less than 50% of the basal level. Active secretion is restored 3-4 days after discontinuation of the drug. With Zollinger-Ellison syndrome, the effect is longer.
Pharmacokinetics:After oral administration, up to 80% is absorbed in the stomach. The maximum concentration is achieved after 1 h. It binds to plasma proteins by 98%. Metabolism in the liver with education inactive metabolites.
The half-life is 1 hour.
Elimination by the kidneys, in the form of metabolites in the amount of 71%. The rest is with feces.
Indications:It is used for the treatment of gastric ulcers and duodenal ulcers, with reflux-esophagitis, Zollinger-Ellison syndrome, ulcerative lesions of the gastric mucosa due to the use of non-steroidal anti-inflammatory drugs.
IV.E15-E16.E16.8 Other specified disorders of internal secretion of the pancreas
XI.K20-K31.K21.0 Gastroesophageal reflux with esophagitis
XI.K20-K31.K20 Esophagitis
XI.K20-K31.K26 Duodenal ulcer
XI.K20-K31.K25 Stomach ulcer
Contraindications:Malignant neoplasms of the gastrointestinal tract.
Individual intolerance.
Carefully:II and III trimester of pregnancy, advanced age, severe hepatic and renal insufficiency.
Pregnancy and lactation:Recommendations for FDA - Category B. Contraindicated in I trimester of pregnancy. Data on penetration into breast milk is not available, during treatment it is recommended to stop breastfeeding.
Dosing and Administration:Inside, not chewing, in the form of capsules of 40-80 mg 1 time / day. The duration of treatment is determined by the effectiveness of the drug and ranges from 2-4 weeks with duodenal ulcer up to 6 months for the purpose of anti-relapse treatment of reflux esophagitis.
The highest daily dose: 80 mg.
The highest single dose: 80 mg.
Side effects:Central and peripheral nervous system: dizziness, headache, anxiety, depression.
Respiratory system: rhinitis, influenza-like syndrome.
The system of hematopoiesis: rarely - thrombocytopenia, anemia.
Digestive system: changes in appetite (increase or decrease), abdominal pain.Rarely, constipation or diarrhea.
Allergic reactions.
Interaction:Reduces the clearance of theophylline by 10%, slows the elimination of drugs that are metabolized in the liver by microsomal oxidation (indirect coagulants, diazepam, phenytoin).
Slows the pH-dependent absorption of drugs from weak acid groups and accelerates the absorption of drugs from the base groups.
Antacids reduce and slow the absorption of pantoprazole, so it is necessary to maintain the interval between appointments in 1-2 hours.
Reduces the bioavailability of pantoprazole by 30% sucralfate. The necessary interval between prescriptions of drugs is 30-40 minutes.
Special instructions:Before the beginning of treatment, an endoscopic examination is necessary to exclude malignant neoplasms.